XML 77 R63.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisition (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 05, 2015
Jun. 24, 2015
Feb. 28, 2018
Mar. 03, 2018
Dec. 02, 2017
Sep. 02, 2017
Jun. 03, 2017
Mar. 04, 2017
Nov. 26, 2016
Aug. 27, 2016
May 28, 2016
Mar. 03, 2018
Mar. 04, 2017
Feb. 27, 2016
Apr. 02, 2015
Final purchase price allocation                              
Goodwill       $ 1,421,120       $ 1,682,847       $ 1,421,120 $ 1,682,847 $ 1,680,843  
Estimated Useful Life                       10 years      
Acquisition costs                       $ 0 6 27,402  
Unaudited pro forma combined financial data                              
Bridge loan commitment fees incurred with the Acquisition by both the Company and EnvisionRx                       15,375      
Net revenues       5,394,264 $ 5,353,170 $ 5,345,011 $ 5,436,523 5,903,385 $ 5,669,111 $ 5,629,559 $ 5,725,485 21,528,968 22,927,540 20,770,237  
Less pre-acquisition intercompany revenue                           (103,363)  
Pro forma combined revenues                       21,528,968 22,927,540 22,402,509  
Net income       767,072 81,031 170,716 (75,349) (21,142) 15,010 14,773 (4,588) 943,470 4,053 165,465  
Net loss before income taxes       (266,954) (34,243) 305,810 (48,158) 23,208 18,928 9,915 (3,533) (43,545) 48,518 151,600  
Incremental interest expense on the 6.125% Notes issued on April 2, 2015                           (11,097)  
Incremental amortization resulting from fair value adjustments of the identifiable intangible assets                           (14,297)  
Transaction costs incurred by both the Company and EnvisionRx                           56,194  
Interest expense incurred by EnvisionRx       50,603 50,308 50,857 51,000 53,391 50,303 49,703 46,668 202,768 200,065 186,132  
Debt extinguishment charges incurred by EnvisionRx     $ (8,180)                 (8,180)   (33,205)  
Income tax expense relating to pro forma adjustments                           (15,866)  
Pro forma net income                       943,470 4,053 188,677  
Net income (loss) from discontinued operations       1,250,745 $ 99,213 $ (17,644) $ (39,312) 3,912 $ (8,600) $ 8,737 $ (4,076) 1,293,002 (27) 63,377  
Pro forma net (loss) income from continuing operations                       $ (349,532) $ 4,080 $ 125,300  
Basic (loss) income per share:                              
Continuing operations                       $ (0.33) $ 0.00 $ 0.12  
Discontinued operations                       1.23 0.00 0.06  
Net basic income per share                       0.90 0.00 0.18  
Diluted (loss) income per share:                              
Continuing operations                       (0.33) 0.00 0.12  
Discontinued operations                       1.23 0.00 0.06  
Net diluted income per share                       $ 0.90 $ 0.00 $ 0.18  
Pharmacy Services                              
Final purchase price allocation                              
Goodwill   $ 1,639,355   1,377,628       1,639,355       $ 1,377,628 $ 1,639,355 $ 1,637,351  
Amount of goodwill deductible for tax purpose   $ 1,368,657                          
Unaudited pro forma combined financial data                              
Net revenues                       5,896,669 6,393,884 4,103,513  
6.125% senior notes due 2023                              
Acquisition                              
Principal amount of debt       $ 1,800,000       $ 1,800,000       $ 1,800,000 $ 1,800,000    
Debt instrument, stated interest rate (as a percent)       6.125%       6.125%       6.125% 6.125%    
EnvisionRx                              
Acquisition                              
Ownership interest (as a percent)   100.00%                          
Stock consideration (in shares)   27,754                          
Share price   $ 8.68                          
Final purchase price                              
Cash consideration $ 116,057 $ 1,882,211                          
Stock consideration   240,907                          
Total   2,123,118                          
Final purchase price allocation                              
Cash and cash equivalents   103,834                          
Accounts receivable   892,678                          
Inventories   7,276                          
Prepaid expenses and other current assets   13,386                          
Total current assets   1,017,174                          
Property and equipment   13,196                          
Intangible assets(1)   646,600                          
Goodwill   1,639,355                          
Other assets   7,219                          
Total assets acquired   3,323,544                          
Accounts payable   491,672                          
Reinsurance funds held   381,225                          
Other current liabilities(2)   215,770                          
Total current liabilities   1,088,667                          
Other long term liabilities(3)   111,759                          
Total liabilities assumed   1,200,426                          
Net assets acquired   2,123,118                          
Estimated Fair Value of Finite lived intangible assets   646,600                          
EnvisionRx | Trademarks                              
Final purchase price allocation                              
Estimated Fair Value of Finite lived intangible assets   33,500                          
EnvisionRx | Customer relationships                              
Final purchase price allocation                              
Estimated Fair Value of Finite lived intangible assets   $ 465,000                          
Estimated Useful Life   17 years                          
EnvisionRx | CMS license                              
Final purchase price allocation                              
Estimated Fair Value of Finite lived intangible assets   $ 57,500                          
Estimated Useful Life   25 years                          
EnvisionRx | Claims adjudication and other developed software                              
Final purchase price allocation                              
Estimated Fair Value of Finite lived intangible assets   $ 59,000                          
Estimated Useful Life   7 years                          
EnvisionRx | Trademarks                              
Final purchase price allocation                              
Estimated Fair Value of Finite lived intangible assets   $ 20,100                          
Estimated Useful Life   10 years                          
EnvisionRx | Backlog                              
Final purchase price allocation                              
Estimated Fair Value of Finite lived intangible assets   $ 11,500                          
Estimated Useful Life   3 years                          
EnvisionRx | 6.125% senior notes due 2023                              
Acquisition                              
Principal amount of debt                             $ 1,800,000
Debt instrument, stated interest rate (as a percent)                             6.125%
EnvisionRx                              
Unaudited pro forma combined financial data                              
Net revenues                           1,735,635  
Net income                           (45,307)  
Interest expense incurred by EnvisionRx                           21,984  
Debt extinguishment charges incurred by EnvisionRx                           $ 31,601